| Market Cap | $53.31M |
| Revenue (ttm) | $38.00K |
| Net Income | $1.61M |
| EPS | $12.57 |
| Shares Out | 8.64M |
| PE Ratio | 0.49 |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 25,181 |
| Open | $5.18 |
| Previous Close | $4.91 |
| Day's Range | $5.13 - $6.17 |
| 52-Week Range | $2.43 - $10.51 |
| Beta | 2.89 |
| Analysts | none |
| Price Target | n/a |
| Earnings Date | n/a |
About IBO
Impact BioMedical Inc. discovers, develops, and commercializes products and technologies to address unmet needs in human healthcare and wellness for specialty biopharmaceuticals, antivirals, antimicrobials, consumer healthcare, and wellness products in the United States. The company provides Linebacker, a platform of small molecule electrophilically enhanced polyphenol compounds with application in oncology, inflammatory disorders, and neurology; and Laetose technology that is derived from a unique combination of sugar and inositol, which can inhibit the inflammatory and metabolic response of sugar alone. It also develops functional fragrance formulation, a suite of functional fragrances containing specialized botanical ingredients with application as an antimicrobial, and as an additive in insect repellents, detergents, lotions, shampoo, fabrics, and other substances. In addition, the company develops Equivir/Equivir G technology, a novel blend of polyphenols, which have demonstrated antiviral effects for use as health supplements and medications. Further, it is developing 3F (functional fragrance formulation), a formulation of botanical ingredients. Impact BioMedical Inc. was incorporated in 2018 and is based in Houston, Texas. Impact BioMedical Inc. operates as a subsidiary of DSS BioHealth Security, Inc.
What Are Insiders Doing?
View the trades behind this meter — each links to its SEC Form 4 →
Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.
$IBO stock is featured in our Insider Score Rankings, and Insider Trades datasets.
→ All Stock ListsRecently reported changes in IBO holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by IBO's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
IBO Estimated quarterly lobbying spending
Source: U.S. Senate LDA
U.S. Patents
New IBO patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to IBO from public contracts
Source: USAspending.gov
Bull Case vs Bear Case
AI-generated from IBO’s recent data — informational, not investment advice
What’s Behind the Score
Recent Insider Activity
Insider Score Trend Over Time
+0.0 since Sep 25Composite Insider Score (0–100) recomputed on each scoring run from live SEC Form 4 data.
